Randomized prospective trial to detect and distinguish between medication nonadherence, drug-drug interactions, and disease progression in chronic cardiometabolic disease
Abstract Background Disentangling nonadherence (NA), drug-drug interactions (DDIs), and disease progression from each other is an important clinical challenge for providers caring for patients with cardiometabolic diseases. NAs and DDIs are both ubiquitous and often overlooked. We studied a novel ch...
Main Authors: | John W Peabody, Divya Ganesan, Czarlota Valdenor, David Paculdo, Joshua Schrecker, Christopher Westerfield, Rebecca Heltsley |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-04-01
|
Series: | BMC Primary Care |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12875-023-02042-4 |
Similar Items
-
Clinical utility of a novel test for assessing cardiovascular disease risk in type 2 diabetes: a randomized controlled trial
by: John W. Peabody, et al.
Published: (2023-07-01) -
The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009–2021
by: Chen Li, et al.
Published: (2023-04-01) -
Nonadherence by Serum Drug Analyses in Resistant Hypertension: 7‐Year Follow‐Up of Patients Considered Adherent by Directly Observed Therapy
by: Lene V. Halvorsen, et al.
Published: (2022-09-01) -
Polypharmacy in chronic liver disease patients: Implications for disease severity, drug-drug interaction, and quality of life
by: Juveriya Farooq, et al.
Published: (2023-08-01) -
Prevalence of Potential Drug–Drug Interaction Risk among Chronic Kidney Disease Patients in a Spanish Hospital
by: Gracia Santos-Díaz, et al.
Published: (2020-07-01)